Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. ##STR00001##

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Metal-chelating compositions having the structure (1a) wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R.sup.5) (═O)OH groups; (v) —C(═O)OH groups; (vi) —S(═O).sub.2OH groups; and (vii) —OH groups, wherein R.sup.5 is selected from hydrocarbon groups (R) and —OH; R.sup.1 and R.sup.2 may optionally interconnect to form Ring A fused to the ring on which R.sup.1 and R.sup.2 are present; R.sup.3 and R.sup.4 may optionally interconnect to form Ring B fused to the ring on which R.sup.3 and R.sup.4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described. ##STR00001##

Metal-chelating compositions having the structure (1a) wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R.sup.5) (═O)OH groups; (v) —C(═O)OH groups; (vi) —S(═O).sub.2OH groups; and (vii) —OH groups, wherein R.sup.5 is selected from hydrocarbon groups (R) and —OH; R.sup.1 and R.sup.2 may optionally interconnect to form Ring A fused to the ring on which R.sup.1 and R.sup.2 are present; R.sup.3 and R.sup.4 may optionally interconnect to form Ring B fused to the ring on which R.sup.3 and R.sup.4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described. ##STR00001##

According to a method for producing a solid electrolyte that contains a lithium atom, a sulfur atom, a phosphorus atom and a halogen atom, including mixing a complexing agent and a solid electrolyte raw material, a solid electrolyte having a high ionic conductivity is provided using a liquid-phase method.

According to a method for producing a solid electrolyte that contains a lithium atom, a sulfur atom, a phosphorus atom and a halogen atom, including mixing a complexing agent and a solid electrolyte raw material, a solid electrolyte having a high ionic conductivity is provided using a liquid-phase method.

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.